|
COPYRIGHT 2003 International Medical News Group
SAN FRANCISCO -- The big news in biologics from the annual meeting of the American Academy of Dermatology was Dr. Alice B. Gottlieb's announcement of infliximab's unprecedented efficacy in patients with moderate to severe psoriasis.
But other biologic therapies for psoriasis are now available or soon will be, Many offer potentially fewer side effects than the chimeric (mouse-human) IgG1 monoclonal antibody and easier delivery options than infliximab, which is given by slow infusion.
Here are some other highlights, listed by drug, from biologic research presented at the meeting:
* Alefacept. Newly approved by the Food and Drug Administration as the first biologic therapy sanctioned to treat psoriasis, alefacept is marketed as Amevive by Biogen Inc. The fully human fusion protein, delivered by weekly intramuscular injection or intravenous...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
